biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > 5 business days until the expiry of the J&J option

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 24, 2023 6:00pm

129 Views

Post# 35243548

RE:RE:RE:5 business days until the expiry of the J&J option

No, beenthere. It is highly unlikely J&J would go ahead if they thought something "off" was being done. My point is that they could be unwitting accomplices if they weren't paying attention.

My most important point is that deadlines are easily extended when both sides want the deal to happen.

jd

<< Previous

Bullboard Posts

Next >>

Three micro-cap stocks on an upswing worth riding